Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Inclusion Criteria: * ≥ 18 and ≤ 70 years of age * Histological or cytological confirmed solid malignant tumor * ECOG performance status of ≤ 2 * Standard regimen failed or no standard regimen available * Life expectancy of more than 3 months * Duration from the last therapy is more than 6 weeks for nitroso or mitomycin; more than 4 weeks for operation or radiotherapy; more than 4 weeks for cytotoxic agents or growth inhibitors. * Laboratory values: hemoglobin ≥ 9.0g/dl, neutrophils ≥ 1.5×10\^9/L, platelets ≥ 100×10\^9/L , ALT ≤ 2.5 x upper limit of normal (ULN), AST ≤ 2.5 x ULN, serum bilirubin ≤ 1.5 x ULN, serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min, PT, APTT, TT, Fbg normal Exclusion Criteria: * Pregnant or lactating women * Any factors that influence the usage of oral administration * Evidence of CNS metastasis * History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * Intercurrence with one of the following: hypertension, coronary artery disease, arrhythmia and heart failure * Receiving the therapy of thrombolysis or anticoagulation * Abuse of alcohol or drugs * Allergy to the ingredient of the agent or more than two kinds of food and drug * Less than 4 weeks from the last clinical trial * Disability of serious uncontrolled intercurrence infection